Credit Suisse Group AG reissued their underperform rating on shares of AstraZeneca plc (LON:AZN) in a research note released on Friday. Credit Suisse Group AG currently has a GBX 4,000 ($49.50) price target on the biopharmaceutical company’s stock.
Other equities analysts have also issued reports about the company. Citigroup Inc. restated a buy rating on shares of AstraZeneca plc in a research note on Thursday, June 23rd. Societe Generale restated a buy rating and set a GBX 6,900 ($85.40) price target on shares of AstraZeneca plc in a research note on Friday, June 24th. Deutsche Bank AG reiterated a buy rating and issued a GBX 5,600 ($69.31) price objective on shares of AstraZeneca plc in a research note on Friday, June 24th. Berenberg Bank reiterated a buy rating and issued a GBX 4,950 ($61.26) price objective on shares of AstraZeneca plc in a research note on Thursday, June 9th. Finally, Bryan, Garnier & Co reiterated a buy rating on shares of AstraZeneca plc in a research note on Thursday, July 28th. Five analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. The company has a consensus rating of Hold and a consensus target price of GBX 4,952.72 ($61.30).
AstraZeneca plc (LON:AZN) opened at 4958.50 on Friday. AstraZeneca plc has a 12 month low of GBX 3,680.00 and a 12 month high of GBX 5,505.00. The stock’s 50 day moving average price is GBX 5,002.62 and its 200 day moving average price is GBX 4,463.11. The firm’s market capitalization is GBX 62.73 billion.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.